a, Cos7 cells transfected with pCMV-miR-21 and Flag–SMAD1, Flag–SMAD3 or Flag–SMAD2, followed by BMP4 or TGF-β treatment (2 h). RNA-ChIP performed with anti-Flag antibody or non-specific IgG (control), followed by PCR amplification with miR-21 primers (*P < 0.05, compared to no treatment; n = 4). IP, immunoprecipitation. b, After treatment of PASMCs with BMP4 or TGF-β (1 h), endogenous SMAD1/SMAD5, SMAD2/ SMAD3, p68 or DROSHA were immunoprecipitated and subjected to PCR analysis with miR-21, miR-199a or miR-214 primers. As controls, RNA samples untreated with reverse transcriptase (–RT) or immunoprecipitated with non-specific IgG (IgG) were subjected to PCR (*P < 0.05 compared to none; n = 4). c, In vitro pri-miRNA processing assay performed by incubating pri-miR-21 substrate with the nuclear extracts prepared from Cos7 cells treated with vehicle, BMP4 or TGF-β (2 h). nt, nucleotide; error bars represent s.e.m.